BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call

Loading news article.

BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call | WAPE

BioVie Says Phase 2 ADDRESS-LC Trial Of Bezisterim In Long COVID Did Not Achieve Statistical Significance On Any Endpoint In Overall Population, With Significant Results Only In Pre-Specified Subgroups; To Discuss Topline Results On September 15 Call

Article summary

Related companies

Analyzed by WAPE AI.

Comments —